Search
Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation proudly announce that eight distinguished MSK nurses and one nursing team were honored with the 2024 Robbins Family Award for Nursing Excellence. The awards coincide with National Nurses Week (May 6 – 12).
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.
Read up on the latest developments in several key areas of cancer research, including genomic mapping, disease modeling through CRISPR, CAR T therapy, and cancer stem cells.
Read why MSK’s medical team is the best in the nation at treating gynecologic cancers.
Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Both studies were presented today at the 2025 ASCO Annual Meeting in Chicago and simultaneously published in The New England Journal of Medicine.
New MSK research identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife. MSK clinical trials also supported the recent approval of the targeted drug larotrectinib by the FDA.
Twelve students have successfully defended their dissertations and will receive their PhD degrees at Commencement on May 14.
Learn about a clinical trial at Memorial Sloan Kettering that is using plasma donated by MSK employees who have recovered from COVID-19.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Richard J. O’Reilly, MD, was named to the Ninth Annual Giants of Cancer Care®.
Structural biologists at Memorial Sloan Kettering Cancer Center are collaborating with biochemists and cell biologists at The Rockefeller University to study how cells read genetic instructions imprinted on histones, DNA's packaging proteins.